← Back to Clinical Trials
Recruiting NCT05281237

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Trial Parameters

Condition Stage I - II Primary Lung Cancer
Sponsor Beth Israel Deaconess Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 10
Sex ALL
Min Age 22 Years
Max Age N/A
Start Date 2022-06-01
Completion 2026-12-30
Interventions
AveCure 16 Gauge Flexible Microwave Ablation Probe

Brief Summary

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)

Eligibility Criteria

Inclusion Criteria: * Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE. * Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards * Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively * Resection/surgical candidate (lobectomy or greater) * Participants must be at least 22 years old and able to provide consent Exclusion Criteria: * Subjects in whom flexible bronchoscopy is contraindicated * Target nodule \< 1.0 cm * Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor * Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives * Pacemaker, implantable cardioverter, or another electronic implantable device * Patient cannot tolerate bronchoscopy * Patients with coagulopathy

Related Trials